ANNUAL REPORT 2012 - TiGenix
ANNUAL REPORT 2012 - TiGenix
ANNUAL REPORT 2012 - TiGenix
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Under the existing warrant plans, 135,802,<br />
45,268, 454,570, 800,000, 400,000, 500,000,<br />
500,000 and 4,000,000 warrants were<br />
created in May 2004, April 2005, November<br />
2005, February 2007, March 2008, June 2009,<br />
March 2010 and July <strong>2012</strong> respectively.<br />
Under the existing EPIB plans 415,700, 37,850,<br />
61,479, 49,446 and 77,751 <strong>TiGenix</strong> SAU (then<br />
still Cellerix) shares were created in June<br />
2008, September 2008, November 2009, May<br />
2010 and October 2010 respectively. These<br />
shares were held by CX EBIP Agreement, SLU.<br />
Under the 2004, 2005, 2007, 2008, 2009 and<br />
2010 plans, in principle 25 % of the warrants<br />
granted vests on each anniversary of the<br />
date of the grant. Under the July <strong>2012</strong> plan,<br />
in principle 1/3 rd of the warrants granted<br />
vests on the first anniversary of the date of<br />
the grant and 1/24 th of the remaining 2/3 rd of<br />
the warrants granted vests on the last day of<br />
each of the 24 months following the month<br />
of the first anniversary of the date of the<br />
grant. Under all plans, warrants granted will<br />
only vest provided that the beneficiary still<br />
has a relationship with the Company via an<br />
employment contract, a director’s mandate<br />
or another collaboration agreement. The<br />
warrants can only be exercised once vested.<br />
All warrants were granted for free. The<br />
duration of the warrants is about 10 years as<br />
of the respective issue date of the warrants.<br />
Warrants that have not been exercised within<br />
such periods become null and void.<br />
The initial term of the warrants issued in<br />
May 2004, April 2005 and November 2005<br />
was extended to May 13, 2014, within the<br />
limits and under the conditions set out in<br />
article 47, §5 of the Law of March 26, 1999<br />
regarding the Belgian action plan for the<br />
employment 1998 as introduced by article 21<br />
of the Economic Recovery Law of March 27,<br />
2009. The other terms and conditions of the<br />
respective warrants remained unchanged.<br />
In the framework of the contribution of<br />
all <strong>TiGenix</strong> SAU (previously Cellerix SA)<br />
shares to <strong>TiGenix</strong> NV on May 3, 2011 (the<br />
“Contribution”), CX EBIP Agreement, SLU<br />
contributed its 642,226 <strong>TiGenix</strong> SAU shares<br />
into <strong>TiGenix</strong> NV and received 1,905,144<br />
<strong>TiGenix</strong> NV shares in return. Therefore,<br />
as a result of the Contribution, CX EBIP<br />
Agreement, SLU no longer holds <strong>TiGenix</strong><br />
SAU shares, but holds 1,905,144 <strong>TiGenix</strong> NV<br />
shares instead. Pursuant to the agreements<br />
reached in relation to the Contribution, the<br />
underlying assets of the options are no longer<br />
the <strong>TiGenix</strong> SAU shares, but the <strong>TiGenix</strong> NV<br />
shares received by CX EBIP Agreement, SLU.<br />
Therefore, upon the exercise of its options<br />
under any of the EBIPs, a beneficiary will<br />
receive a number of <strong>TiGenix</strong> NV shares<br />
corresponding to approximately 2.96 shares<br />
per option (rounded down to the nearest<br />
integer) under any of the EBIPs.<br />
5. Discussion of the main risks<br />
and uncertainties<br />
The main risks and uncertainties involved<br />
in the Company’s business include the<br />
following :<br />
- <strong>TiGenix</strong> has a history of operating losses and<br />
an accumulated deficit until today and<br />
may never become profitable.<br />
Prior to the business combination of the<br />
Company with <strong>TiGenix</strong> SAU, <strong>TiGenix</strong> SAU had<br />
created two Equity Based Incentive Plans<br />
(“EBIPs”).<br />
- <strong>TiGenix</strong> may need substantial additional<br />
funding, which may not be available on<br />
acceptable terms when required, if at all.<br />
176 <strong>TiGenix</strong> I annual report <strong>2012</strong>